Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Investment analysts at William Blair decreased their Q3 2025 earnings per share (EPS) estimates for Krystal Biotech in a report released on Wednesday, July 9th. William Blair analyst S. Corwin now anticipates that the company will post earnings per share of $1.57 for the quarter, down from their prior forecast of $1.84. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share. William Blair also issued estimates for Krystal Biotech's FY2025 earnings at $5.89 EPS and FY2026 earnings at $8.19 EPS.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.18). The firm had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million. Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%.
KRYS has been the topic of several other reports. HC Wainwright reaffirmed a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a research report on Tuesday, June 24th. Citigroup reaffirmed a "neutral" rating and issued a $176.00 price objective (up from $155.00) on shares of Krystal Biotech in a research report on Wednesday, July 9th. Guggenheim lowered their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, Chardan Capital reiterated a "buy" rating and set a $219.00 target price on shares of Krystal Biotech in a research note on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $213.75.
Get Our Latest Report on Krystal Biotech
Krystal Biotech Stock Performance
Shares of KRYS traded down $1.26 during mid-day trading on Monday, reaching $149.15. The company had a trading volume of 20,954 shares, compared to its average volume of 286,364. The firm has a 50-day moving average price of $135.59 and a 200 day moving average price of $156.16. Krystal Biotech has a 52 week low of $122.80 and a 52 week high of $219.34. The company has a market capitalization of $4.31 billion, a price-to-earnings ratio of 36.14 and a beta of 0.67.
Institutional Trading of Krystal Biotech
Large investors have recently made changes to their positions in the stock. US Bancorp DE lifted its position in shares of Krystal Biotech by 8.7% during the fourth quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after buying an additional 82 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Krystal Biotech by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 243,170 shares of the company's stock valued at $38,095,000 after purchasing an additional 2,954 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Krystal Biotech in the 4th quarter valued at approximately $15,989,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Krystal Biotech by 31.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,054 shares of the company's stock valued at $948,000 after purchasing an additional 1,440 shares during the last quarter. Finally, Swiss National Bank grew its holdings in Krystal Biotech by 8.4% in the fourth quarter. Swiss National Bank now owns 42,400 shares of the company's stock valued at $6,642,000 after purchasing an additional 3,300 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other Krystal Biotech news, insider Suma Krishnan sold 6,927 shares of Krystal Biotech stock in a transaction on Thursday, July 10th. The shares were sold at an average price of $150.27, for a total transaction of $1,040,920.29. Following the completion of the transaction, the insider directly owned 1,525,929 shares of the company's stock, valued at $229,301,350.83. The trade was a 0.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 13,927 shares of company stock worth $2,092,852 over the last ninety days. 13.70% of the stock is owned by insiders.
Krystal Biotech Company Profile
(
Get Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Further Reading
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
